The enhanced HER2 expression in G2/M cells implies a greater likelihood of gemcitabine effectively binding with trastuzumab emtansine (T-DM1, HER2 targeted with DM1 payload), which contributes to the improved efficacy of the combination on pancreatic ductal adenocarcinoma cells [15]. Here, ERBB2 is linked to pancreatic ductal adenocarcinoma.